Alzheimer’s disease genetics and real‐world patient data fuel target and drug discovery in European and African American Ancestries using AI/ML approaches
Combining genetics and real-world patient data identifies ancestry-specific therapeutic targets and medicines for AD. Further functional and clinical validation of candidate targets and drugs in ethnically diverse population are warranted.
Authors
- Jonathan L. Haines (ORCID: https://orcid.org/0000-0002-4351-4728)
- Feixiong Cheng (ORCID: https://orcid.org/0000-0002-1736-2847)
- Bruce D. Hammock (ORCID: https://orcid.org/0000-0003-1408-8317)
- Cindy B. McReynolds (ORCID: https://orcid.org/0000-0003-3309-1773)
- James B. Leverenz (ORCID: https://orcid.org/0000-0002-0896-0749)
- Jeffrey L. Cummings (ORCID: https://orcid.org/0000-0001-8944-4158)
- Andrew A. Pieper (ORCID: https://orcid.org/0000-0001-6299-6577)
- Pengyue Zhang (ORCID: https://orcid.org/0000-0002-7381-9303)
- Fan Fan (ORCID: https://orcid.org/0000-0003-1463-3610)
- Yuan Hou
Institutions
- Cleveland Clinic (US)
- University of Nevada, Las Vegas (US)
- Augusta University (US)
- Lou Ruvo Brain Institute (US)
- Indiana University Bloomington (US)
- Eicosis (United States) (US)
- University School (US)
- Case Western Reserve University (US)
- University of California, Davis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.087887
- Citations
- 1
- Primary Topic
- Artificial Intelligence in Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 0.71